Sclerostin: Another bone-related protein related to all-cause mortality in haemodialysis?

Nephrology Dialysis Transplantation

Volumn 28, Issue 12, 2013, Pages 3024-3030

  Viaene, Liesbeth ^a   Behets, Geert J ^c   Claes, Kathleen ^a   Meijers, Bjorn ^a   Blocki, Franck ^d   Brandenburg, Vincent ^b   Evenepoel, Pieter ^a   D'Haese, Patrick C ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Diasorin SpA   (Italy)

Author keywords

All cause mortality; Haemodialysis; Sclerostin

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CREATININE; HEMOGLOBIN; SCLEROSTIN;

AGE; AGED; ARTICLE; BLOOD SAMPLING; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

ALL-CAUSE MORTALITY; HAEMODIALYSIS; SCLEROSTIN;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; CAUSE OF DEATH; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION;

EID: 84885664875     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft039     Document Type: Article

References (44)

1. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
2. Roman-Garcia P, Carrillo-Lopez N, Fernandez-Martin JL et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010; 46: 121-128
3. Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 2012; 8: 529-543
4. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007; 148: 2635-2643
5. Wei W, Zeve D, Suh JM et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin. Mol Cell Biol 2011; 31: 4706-4719
6. Drueke TB, Lafage-Proust MH. Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol 2011; 6: 700-703
7. Modder UI, Hoey KA, Amin S et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011; 26: 373-379
8. Ardawi MS, Al-Kadi HA, Rouzi AA et al. Determinants of serum sclerostin in healthy pre-and postmenopausal women. J Bone Miner Res 2011; 26: 2812-2822
9. Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: 234-241
10. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882
11. Caira FC, Stock SR, Gleason TG et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006; 47: 1707-1712
12. Shao JS, Cheng SL, Pingsterhaus JM et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005; 115: 1210-1220
13. Zhu D, Mackenzie NC, Millan JL et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011; 6: e19595
14. Poole KE, van Bezooijen RL, Loveridge N et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19: 1842-1844
15. Drake MT, Srinivasan B, Modder UI et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010; 95: 5056-5062
16. Meijers BK, Van KS, Verbeke K et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009; 54: 891-901
17. Van Hoof VO, Hoylaerts MF, Van MM et al. Identification of intestinal, intestinal variant, and high-Mr alkaline phosphatase with the resolve-ALP isoelectric focusing system. Clin Chem 1991; 37: 304-305
18. Bouillon R, Coopmans W, Degroote DE et al. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem 1990; 36: 271-276
19. Daugirdas JT. Second generation logarithmic estimates of singlepool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213
20. Depner TA, Daugirdas JT. Equations for normalized protein catabolic rate based on two-point modeling of hemodialysis urea kinetics. J Am Soc Nephrol 1996; 7: 780-785
21. Coyne D, Acharya M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276
22. Koos R, Brandenburg V, Mahnken AH et al. Sclerostin as potential novel biomarker for aortic valve calcification: An in vivo and ex vivo study. Heart 2012; epub
23. Shanahan CM, Crouthamel MH, Kapustin A et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711
24. Neven E, Persy V, Dauwe S et al. Chondrocyte rather than osteoblast conversion of vascular cells underlies medial calcification in uremic rats. Arterioscler Thromb Vasc Biol 2010; 30: 1741-1750
25. Cejka D, Jager-Lansky A, Kieweg H et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 226-230
26. Gaudio A, Privitera F, Battaglia K et al. Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: 3744-3750
27. Thambiah S, Roplekar R, Manghat P et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012; 90: 473-480
28. Claes K, Viaene L, Heye S et al. Circulating sclerostin levels and vascular calcification in chronic kidney disease: a complex relationship. 45th ASN Congress 2012, TH-PO 886
29. Ke HZ, Richards WG, Li X et al. Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012; 33: 747-783
30. Budoff MJ, Rader DJ, Reilly MP et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis 2011; 58: 519-526
31. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
32. Lomashvili KA, Garg P, Narisawa S et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcification. Kidney Int 2008; 73: 1024-1030
33. Towler DA. Inorganic pyrophosphate: a paracrine regulator of vascular calcification and smooth muscle phenotype. Arterioscler Thromb Vasc Biol 2005; 25: 651-654
34. Riser BL, Barreto FC, Rezg R et al. Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. Nephrol Dial Transplant 2011; 26: 3349-3357
35. Power J, Poole KES, van Bezooijen R et al. Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture. J Bone Miner Res 2010; 25: 1867-1876
36. Devarajan-Ketha H, Craig TA, Madden BJ et al. The sclerostin-bone protein interactome. Biochem Biophys Res Commun 2012; 417: 830-835
37. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203
38. Drechsler C, Verduijn M, Pilz S et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011; 6: 1752-1759
39. Shantouf R, Kovesdy CP, Kim Y et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1106-1114
40. Iba K, Takada J, Yamashita T. The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patients. J Bone Miner Metab 2004; 22: 594-596
41. Atkins GJ, Rowe PS, Lim HP et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res 2011; 26: 1425-1436
42. Cannata-Andia JB, Roman-Garcia P, Hruska K. The connections between vascular calcification and bone health. Nephrol Dial Transplant 2011; 26: 3429-3436
43. Schulz E, Arfai K, Liu X et al. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004; 89: 4246-4253
44. Rodriguez-Garcia M, Gomez-Alonso C, Naves-Diaz M et al. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 239-246